INTRODUCTION
Developing effective cytotoxic monoclonal antibody therapies against multiple myeloma has been hampered by lack of target molecules that are unique and constitutively expressed on all myeloma cells. Therapies felt to have promise have included anti-CD20 (rituximab, or the toxin conjugated variant) 1, 2 , anti-CD40 3 , anti-CD52 (alemtuzumab) 4 , anti-CD74 5 , anti-CD126
(atlezumab) 6, 7 , and anti-CD138 8 . Unfortunately, these agents have often shown limited utility against myeloma.
Monoclonal antibodies may have had limited efficacy against myeloma tumor cells for at least three reasons. Many of the targeted surface markers, for example CD52 and CD20, are down-regulated in mature plasma cells and expressed on only a subset of myelomas 2, 9 . In addition, antibody depletion of cells bearing myeloma specific markers such as CD138 (Syndecan-1)
does not prevent reemergence of the primary clone from CD138 -bone marrow precursors.
Myeloma bone marrow aspirates depleted of CD138 + cells will, after several weeks, generate new CD138 expressing myeloma cells identical to those depleted. 10 These putative "myeloma stem cells" express several surface markers similar to those found in post-germinal center B cells, along with molecular markers common to their more differentiated CD138 + progeny. 10 Finally, some myeloma cells escape complement dependent antibody-mediated cytotoxicity by expressing complement cascade inhibitors, such as CD59 11 or are resistant to pro-apoptotic signals. 12, 13 Polyclonal antibody preparations may have several advantages over monoclonal therapeutic agents, including the ability to target multiple surface proteins and simultaneously trigger several parallel or additive pathways for cell death. This may be a distinct advantage when atFor personal use only. on September 24, 2017 . by guest www.bloodjournal.org From rATG Induced Myeloma Cell Death Zand, et al.
-4 of 31 -tempting to eradicate myeloma cells which emerge from a common less differentiated precursor 10, 14 and may be responsive to coordinate activation of several cell death pathways. 13, 15 We have recently described the ability of rabbit polyclonal anti-thymocyte globulin (rATG) to induce apoptosis of normal naïve, memory, and activated B cells, in addition to normal human plasma cells. 16, 17 Anti-thymocyte globulin is prepared by immunizing rabbits with non-fractionated human thymocytes isolated by Ficoll density gradient centrifugation. This crude innoculum contains CD20 + B and CD138 + plasma cells 17, 18 , which constitute approximately 5% of thymocytes [19] [20] [21] . Consistent with this finding, we have described the presence of anti-CD20, -CD38, and -CD138 specific activity in rATG. 17 In this report, we describe the induction of apoptosis, as well as complement mediated cell lysis, by rATG in fresh myeloma cells and myeloma cell lines, identify some of the antigens against which the activity is directed, and describe several pathways of rATG induced cell death in myeloma cells.
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-5 of 31 - MCI (RPMI-8226, ARH-77, NCI-H929), MC2 (U266) and MC3 (MC-CAR) and were obtained from the American Tissue Culture Collection (ATCC, Manassas, VA). All cells were incubated in 5% CO 2 at 37°C and saturated humidity. CD40L stimulated human B cells and CpG generated human plasma cells were prepared and cultured as previously described. 17, 22, 23 Human bone marrow stromal cells were isolated from bone marrow aspirates of normal volunteers and cultured as previously described.
MATERIALS AND METHODS

Human subjects protection:
24
Sources of myeloma cells and cell lines: Primary myeloma cells were isolated from patient bone marrow aspirates. Cells were initially separated by Ficoll density gradient centrifugation and washed in PBS twice. CD138 + cells were then incubated with anti-CD138 antibodies coupled magnetic beads and positively selected on a magnetic affinity column (Miltenyi) as previously described 17, 23 . The resulting cells were then washed twice in PBS and used for experiments. The percentage of myeloma infiltrate in the bone marrow was quantified by flow cytometric analysis of -and -light chain expression as previously described.
17,23
For personal use only. -7 of 31 -Cambridge MA) was purchased from the pharmacy and 10 mM stock was prepared by resuspension in 0.9% saline.
Measurement of apoptosis:
Induction and measurement of apoptosis was performed as previously described. For each experiment, 10 5 cells/well were cultured in 48-well flat-bottom plates in their respective medium. To test their capacity for induction of apoptosis, the following agents were added to the medium: rATG (100 -1000 µg/ml), rituximab (250 µg/ml), alemtuzumab (250 µg/ml), or non-immunized rabbit IgG (100 µg/ml) as a negative control. Cells were then incubated for 1-18 hours at 37 ºC. For apoptosis experiments using bone marrow stromal cells, myeloma cells were cultured in 24 well flat bottom plates either directly in contact with stromal cells, or in a transwell which allowed the cells to share media without direct contact.
Induction of apoptosis was assessed by 4 different methods. reagent was used at concentrations equimolar to that of intact rATG.
Immunohistochemical staining of thymic tissue:
A random sample of 10 blocks was selected from 41 normal human pediatric thymuses removed from patients less than ten years old during 2001, New paraffin cut sections were cut and immunoperoxidase staining was performed by previously published methods 25,26 using a streptavidin-biotin detection system, horseradish peroxidase, and 7-aminoethylcarbizole (7-AEC) as the substrate. The primary antibodies were: CD3 (1:100 primary dilution, DAKO, Carpinteria, CA), CD20 (1:800 dilution, clone L26, DAKO), CD73 (1:100, DAKO), and CD138 (1:100, syndecan-1, clone B-B4, Serotec, Kidlingston, UK). 25 Images were photographed with a Nikon Labophot microscope using a 40x (0.75 n.a.) and 100x (1.30 n.a.) oil objective lens. Images were recorded with a Nikon Coolpix digital camera using the manufacturer's software. JPEG images were viewed with Adobe Photoshop and contrast adjusts made.
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From Statistical analysis -Statistical analyses was performed using Statistica version 6 software (Statsoft, Tulsa OK) on a Windows XP operating system. Comparisons between groups of apoptotic conditions were performed using Student's T test (two sided). 27 Thus, we next tested whether the presence of bone marrow stroma conveyed any protection to rATG induced apoptosis. First, myeloma cell lines were incubated with rATG 250 µg/ml in the presence or absence of varying concentrations of IL-6 ( Figure 2B ). No difference in the efficacy of rATG induced apoptosis was observed. Next, myeloma cell lines were cultured in trans-well plates so that they were exposed to stromal cell secreted factors (SS), or in direct contact with primary bone marrow stromal cultures (SC; Figure 2B ). We found several patterns of stromal cell effect on apoptosis.
RESULTS
Induction
NCI-H929 cells had reduced apoptosis in rATG when cultured in contact (SC) with stroma, but this effect was lost when cultured in trans-well plates. In contrast, MC-CAR and U266 cells had modest reductions in apoptotic sensitivity with either contact or non-contact co-culture. We were therefore interested to see if there was any synergy between rATG and these agents in induction of apoptosis ( Figure 3B ). No increase in rATG induced apoptosis was seen with either Sirolimus (10 ng/ml), bortezomib (10 nM) or dexamethasone (100 µM). Myeloma cell lines were incubated with clinically relevant concentrations of sirolimus and increasing concentrations of rATG ( Figure 2D ). No increase in rATG induced apoptosis was seen over a sirolimus concentration range of 0.1-100 ng/ml, and similar results were obtained with dexamethasone and bortezomib (data not shown). What are the targets of rATG on myeloma cells? The observation that rATG can induce myeloma cell death by complement independent and dependent mechanisms suggests that rATG has activity against specific surface markers on myeloma cells, To determine if rATG contained antibodies directed at cell surface proteins linked to pro-apoptotic pathways or growth factor receptor pathways (e.g. IL-6R) we performed competitive binding studies using myeloma cell lines. Given previous data describing the emergence of a putative myeloma stem cell capable of regenerating CD138 + myeloma clones 10,14 , we also tested for rATG activity against a variety of pre-plasma cell surface markers expressed on naïve, and CD40L activated B cells. Cells and cell lines used in these experiments were selected for expression of the target molecule of interest. Cells were incubated in either rATG or unimmunized rabbit Ig for 1 hour at 37 °C, followed by labeling with monoclonal antibodies specific for known pro-apoptotic B cell and myeloma 
Complement and FcR
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Why does rATG contain antibodies against CD138
+ myeloma and plasma cells? Antithymocyte globulin is made by immunizing rabbits against unfractionated, Ficoll isolated preparations of normal human pediatric thymocytes. The finding of B cell and plasma cell specific antibodies, such as those directed against CD20, CD79 and CD138, suggests that these prepara- -16 of 31 -surface marker expression, but cell surface phenotypes may vary in different treatment phases as the malignant clone becomes more or less differentiated. In myeloma, the recognition of the "myeloma stem cell" phenomenon, where CD138 myeloma cells can emerge from CD138 negative, phenotypically "normal" B cell precursors, raises doubts as to whether a single monoclonal antibody will be effective for tumor ablation. This theoretical issue, coupled with our observation that polyclonal rabbit anti-thymocyte globulin has pro-apoptotic activity against human plasma cells, suggested to us that rATG might be a candidate agent for treatment of myeloma.
Early laboratory investigations indicated that rATG had pro-apoptotic activity against B cells and human B cell lines. Bonnefoy-Berard and colleagues showed that rATG had binding activity against CD11a, CD18, CD45, CD3, CD5, HLA-DR, CD2, CD4, CD8 and CD25, some of which were expressed by B lymphocytes. 34 We have recently demonstrated that rATG induced high levels of apoptosis in human naïve, memory and activated B cells, as well as plasma cells, and identified many B cell specific surface markers that are targets for rATG. 17 We now extend this observation to myeloma cell lines and primary cultures. In this report, we characterize in detail the activity of rATG against human myeloma cell lines and CD138 + myeloma cells from primary bone marrow aspirates. As measured by multiple assays, rATG induced complement independent apoptosis in virtually all myeloma cell lines and primary isolates tested. This complement independent apoptosis was partially blocked by inhibitors of cathepsin B and the pan-caspase inhibitor z-VAD-fmk. The presence of complement, as one would expect in vivo, significantly increased myeloma cell death, even for those cell lines and primary myeloma cell isolates that did not undergo substantial apoptosis.
Polyclonal anti-thymocyte globulins have been used as immunosuppressive agents in solid organ and bone marrow transplantation and in the treatment of graft versus host disease. and augment the ability of low levels of IL-6 to support myeloma cell growth. Blockade of EGF signaling sensitizes these myeloma cells to anti-IL-6 or dexamethasone induced apoptosis. 44 Interestingly, EGF receptors are also present on immature thymocytes. 45 In light of this and the It is interesting to note that binding of rATG to the FcR appears to increase the efficacy of rATG induced apoptosis for many myeloma cell lines. This appears to be a consequence of FcR crosslinking and FcR ligation, as this activity can be restored when F(ab) 2 fragments of rATG are combined with either divalent antibodies that crosslink, or monovalent Fc fragments which bind to, the Fc II receptor. Ligation of the FcR in B cells under certain conditions has been reported to induce apoptosis 46 , and FcR heterogeneity may also explain the differential sensitivity of some lupus patients to treatment with anti-CD20. 47 Thus, particularly for myeloma cells which express the Fc II, it seems advantageous to have antibodies with a functional Fc region for both complement binding and for apoptosis induction.
Many of the specificities of rATG relevant to B cells have known roles in apoptosis signaling. Thus, a polyclonal approach may be advantageous when targeting myeloma cells, which may be heterologous in their susceptibility to any single monoclonal antibody. We observed this phenomenon in this study, with differential sensitivity among myeloma cell lines to the different modes of cell death induced by rATG (caspase or cathepsin mediated apoptosis, complement mediated lysis). Another potential approach to this problem would be to create "polymonoclonal" reagents: defined mixtures of monoclonal antibodies that target multiple surface proteins expressed at different stages of lymphocyte development.
One potential issue with this strategy is that we did not determine the relative concentrations of B versus T cell directed antibodies in the rATG preparations. It is therefore possible that clinical anti-B cell activity of rATG may be inadequate to "de-bulk" the pre-plasma cell compartment of patients with a high myeloma cell burden. In such cases, we speculate that it may be A related issue is the risk of infection with rATG therapy in myeloma given its ability to deplete the T cell compartment. Infections related to T cell depletion tend to be those of viral origin, including cytomegalovirus, Epstein-Barr virus, parvovirus, adenovirus, and herpesviruses.
However, the experience in solid organ transplantation has shown that the T cell compartment recovers within 1-2 months, making this a manageable issue. In addition, one might consider a clinical treatment strategy that involved leukopheresis and isolation of CD3+ T cells, which can then be re-infused when rATG levels fall. Finally, rATG appears to have only modest and temporary effects against normal hematopoietic cells. The extensive experience with rATG in treatment of aplastic anemia has shown that the hematologic response to ATG therapy is associated with increased numbers of hematopoietic progenitors post-treatment 48 . Supporting this observation is the finding that CD34+ hematopoietic stems cells from normal individuals are Fas negative and insensitive to rATG induced apoptosis. 49 Clinical recovery of hematopoietic progenitor compartment may be also improved with administration of granulocyte colonystimulating factor. 50 The results reported here lead us to hypothesize that rATG may have utility as a component of clinical regimen for myeloma and plasma cell malignancies. Further careful clinical study will be need to examine this possibility, as positive in vitro results may not be predictive of in vivo outcomes. Response to rATG therapy may vary among patients as clonal sensitivity to the multiple apoptosis pathways varies. In addition, the marrow microenvironment may convey additional protection from rATG induced apoptosis or complement mediated lysis. We would Annexin V TOPRO-3 0.1 µg/ml 1 µg/ml 10 µg/ml 100 µg/ml 1000 µg/ml 
